Posted inCardiagtech

Differential Diagnosis of Bipolar Disorder: A Comprehensive Guide

No Comments

Bipolar disorder, also known as bipolar affective disorder, ranks as a significant cause of disability globally. Characterized by recurrent mood episodes of mania or hypomania alternating with depression, bipolar disorder often presents diagnostic challenges. Effective management relies on pharmacotherapy and psychosocial interventions, yet mood relapses and incomplete responses, particularly in depressive phases, are common. Long-term care necessitates continuous assessment and treatment adjustments, often alongside the management of comorbid psychiatric and medical conditions. This article delves into the differential diagnosis of bipolar disorder, providing a detailed guide for clinicians to distinguish it from other conditions with overlapping symptoms.

Introduction

Bipolar disorder (BD) is defined by the cyclical occurrence of mania or hypomania and depressive episodes, frequently leading to initial misdiagnosis. The spectrum of bipolar and related disorders encompasses bipolar I disorder (BD-I), bipolar II disorder (BD-II), cyclothymic disorder, other specified bipolar and related disorders, and unspecified bipolar or related disorders. The shift from “bipolar affective disorders” in ICD-10 to “bipolar and related disorders” in ICD-11 and DSM-5 reflects a broader understanding of this spectrum.

Global prevalence studies reveal a consistent lifetime prevalence of the bipolar spectrum, approximately 2.4%, encompassing BD-I, BD-II, and subthreshold bipolar conditions. The complexity of BD diagnosis arises from symptom overlap with other psychiatric disorders, frequent psychiatric and medical comorbidities, and patients’ potential lack of awareness, especially during hypomanic phases. While treatment strategies involve both medication and psychosocial support, managing mood fluctuations and achieving full remission, particularly from depression, remains a challenge. Continuous monitoring and adaptation of treatment plans are crucial for long-term patient care, including addressing co-existing psychiatric and chronic medical conditions. This discussion focuses on the crucial aspect of differential diagnosis in bipolar disorder.

Etiology and Diagnostic Overlap

The exact cause of BD remains unclear, attributed to a complex interplay of genetic predispositions, epigenetic factors, neurochemical imbalances, and environmental influences. The heritability of bipolar disorder is well-documented. Genetic research has identified numerous loci that increase BD susceptibility, with over 30 genes linked to heightened risk.

Environmental factors, particularly early life adversities such as emotional abuse or neglect, are implicated in BD development. Stressful life events, including childbirth, divorce, job loss, disability, and early parental bereavement, are also associated. Adults with BD frequently report experiencing significant stressful events in the months preceding manic or depressive episodes.

Neurochemically, BD is thought to involve disruptions in monoaminergic neurotransmitter systems, notably dopamine and serotonin, and mood-regulating intracellular signaling pathways. However, no single neurotransmitter dysfunction has been definitively identified.

Neuroimaging studies suggest widespread brain alterations in BD, including reduced subcortical volumes, decreased cortical thickness, and altered white matter integrity compared to healthy individuals. Changes in functional connectivity have also been observed. These neurobiological underpinnings contribute to the clinical presentation of BD, which can mimic other psychiatric disorders, emphasizing the importance of differential diagnosis.

Epidemiology and Diagnostic Challenges

Epidemiological surveys indicate that despite variations in prevalence across different regions, the severity, impact, and comorbidity patterns of bipolar spectrum disorders are remarkably consistent worldwide. The lifetime prevalence rates are approximately 0.6% for BD-I, 0.4% for BD-II, and 1.4% for subthreshold BD, totaling 2.4% for the bipolar spectrum.

The onset of bipolar disorder typically occurs during two age peaks: 15-24 years and 45-54 years, with over 70% of individuals showing symptoms before age 25. BD affects both sexes and various ethnicities equally, and shows similar prevalence in urban and rural settings. Cyclothymia has a lifetime prevalence of about 0.4-1% and an even male-to-female ratio.

The early onset and fluctuating nature of bipolar disorder, coupled with the overlap of symptoms with conditions like major depressive disorder, anxiety disorders, and personality disorders, contribute to diagnostic delays and misdiagnosis. This underscores the critical need for careful differential diagnosis to ensure appropriate treatment and management.

Pathophysiology and Symptom Mimicry

The pathophysiology of BD, like its etiology, is complex and likely involves interactions between genetic, neurochemical, and environmental factors. Research highlights genetic and epigenetic contributions, with evidence of altered levels of neurotrophic factors like brain-derived neurotrophic factor (BDNF) in BD patients, suggesting impaired neuroplasticity. Mitochondrial dysfunction, oxidative stress, immune-inflammatory imbalances, and hypothalamic-pituitary-adrenal axis dysregulation are also implicated. Neuroimaging further reveals changes in brain activity, connectivity, and neuronal structure.

Imbalances in monoaminergic neurotransmitter systems, particularly dopamine and serotonin, are believed to play a role, though no specific neurotransmitter dysfunction has been pinpointed. These complex neurobiological changes manifest clinically in mood disturbances, energy level shifts, and cognitive alterations that can resemble symptoms of other psychiatric conditions. Therefore, a thorough differential diagnosis process is essential.

History, Physical Examination, and Differential Diagnosis

Bipolar disorder diagnosis is primarily clinical, relying on comprehensive assessment, patient interviews, family history, and longitudinal symptom tracking. Currently, no definitive biomarkers or neuroimaging tools aid in diagnosis. A significant challenge in diagnosing bipolar disorder is the considerable delay, often 6 to 10 years, between symptom onset and correct diagnosis. This delay highlights the difficulties in differentiating BD from other conditions.

Misdiagnosis often occurs because initial presentations frequently resemble major depressive disorder (MDD), the most common initial diagnosis before BD is recognized. A significant proportion, 20-30%, of patients initially diagnosed with MDD eventually transition to a bipolar disorder diagnosis within three years. Clinicians must be vigilant for this transition, particularly in MDD patients who initially screen negative for bipolarity. Subthreshold hypomanic symptoms may also be present in up to 40% of MDD patients, further complicating the differential diagnosis.

Screening tools like the Mood Disorders Questionnaire (MDQ) and the Hypomania Checklist 32 (HCL-32) can aid in identifying potential BD cases, though they are not definitive diagnostic tools. Positive screening results should prompt a thorough clinical evaluation for bipolar disorder.

Distinguishing between unipolar and bipolar depression is particularly challenging as both share similar depressive episode criteria. Key historical factors that increase suspicion for bipolar depression include early onset of depression (before age 25), a high number of depressive episodes (five or more), and a family history of bipolar disorder. These historical clues are crucial in the differential diagnosis between unipolar and bipolar depression.

Other indicators suggesting a shift from MDD to BD include the presence of psychosis, lack of response to antidepressants, antidepressant-induced mania or hypomania, and polymorbidity (three or more comorbid conditions). These factors should raise suspicion for bipolar disorder and prompt a reassessment of the initial diagnosis.

Evaluation and Diagnostic Criteria for Differential Diagnosis

DSM-5 Diagnostic Criteria and Differential Considerations

The DSM-5 outlines specific criteria for diagnosing bipolar and related disorders, which are essential for differential diagnosis.

  • BD-I: Requires at least one manic episode. It’s crucial to differentiate mania from substance-induced mood disorders, medical conditions causing mania, and psychotic disorders like schizophrenia or schizoaffective disorder where manic symptoms might be present.

  • BD-II: Requires at least one hypomanic episode and a major depressive episode, with no history of mania. Differential diagnosis includes cyclothymic disorder (milder, chronic mood fluctuations), borderline personality disorder (for mood lability), and ADHD (for impulsivity and distractibility).

  • Cyclothymic disorder: Characterized by chronic, fluctuating mood disturbances with hypomanic and depressive symptoms that don’t meet full episode criteria for mania or major depression. It needs to be differentiated from personality disorders with mood instability and from the normal mood variations of daily life.

  • Specified and Unspecified bipolar and related disorders: These categories are for presentations that don’t fully meet criteria for BD-I, BD-II, or cyclothymia. Differential diagnosis here is broad, requiring careful consideration of other mood disorders, adjustment disorders with mood symptoms, and personality disorders.

Differentiating Manic and Hypomanic Episodes

Manic episodes in BD-I are more severe than hypomanic episodes in BD-II, causing significant functional impairment or requiring hospitalization. The diagnostic criteria for manic and hypomanic episodes are similar, involving elevated mood, increased energy, decreased need for sleep, racing thoughts, and impulsivity. However, the severity and impact distinguish mania from hypomania in differential diagnosis. Psychotic features are present in mania but absent in hypomania.

Differentiating Bipolar Depression from Unipolar Depression

Bipolar depression, part of BD-I or BD-II, and unipolar major depressive disorder (MDD) share depressive symptom criteria. Differential diagnosis relies on identifying any history of manic or hypomanic episodes, which are absent in MDD. Features suggestive of bipolar depression include early onset, psychotic features during depression, psychomotor retardation, atypical depressive symptoms (hypersomnia, increased appetite), and family history of bipolar disorder. Antidepressant-induced mood switching is also a key indicator differentiating bipolar from unipolar depression.

Secondary Causes of Bipolar Symptoms

When evaluating for bipolar disorder, especially with atypical presentations, consider secondary causes. Factors raising suspicion for secondary mania or depression include symptom onset after age 50, abnormal vital signs or neurological findings, recent health changes or medication changes, unusual treatment response, and absence of personal or family psychiatric history. Initial evaluation should include urine drug screen, complete blood count, metabolic panel, thyroid function tests, and vitamin levels to rule out medical or substance-induced mood disorders in the differential diagnosis.

Treatment and Management: Implications for Differential Diagnosis

While treatment guidelines for bipolar disorder exist, variations across guidelines underscore the complexity of managing this condition. For differential diagnosis, it’s important to note how treatment response can further clarify the diagnosis. For example, a patient initially diagnosed with MDD who experiences manic switching on antidepressants is highly likely to have bipolar disorder.

Manic Episode Management and Differential Diagnosis

Acute mania is a psychiatric emergency, often requiring hospitalization. Initial management focuses on patient stabilization and safety. Differential diagnosis in acute mania involves ruling out medical conditions (e.g., hyperthyroidism, neurological disorders) and substance intoxication that can mimic mania.

Hypomanic Episode Management and Differential Diagnosis

Hypomania, less severe than mania, can often be managed in outpatient settings. Differential diagnosis of hypomania includes differentiating it from normal high energy and enthusiasm, ADHD (though hypomania is episodic, ADHD is chronic), and certain personality disorders with impulsivity.

Acute Bipolar Depression Management and Differential Diagnosis

Managing bipolar depression prioritizes suicide risk assessment. Differential diagnosis of bipolar depression from unipolar depression is critical for treatment selection, as antidepressants alone are generally avoided in bipolar depression due to the risk of mood switching. Mood stabilizers and specific antipsychotics are preferred. Lack of response to antidepressants in a presumed MDD patient should prompt reconsideration for bipolar depression.

Maintenance Treatment and Long-Term Diagnostic Stability

Long-term maintenance treatment is usually necessary in bipolar disorder to prevent relapse. Continued monitoring is essential, as diagnostic reevaluation may be needed over time. For instance, some patients initially diagnosed with MDD may later develop clear hypomanic or manic episodes, leading to a diagnosis of bipolar disorder. Long-term observation of symptom patterns and treatment response contributes to refining the differential diagnosis over time.

Differential Diagnosis: Key Conditions to Distinguish from Bipolar Disorder

The differential diagnosis of bipolar disorder is broad, including conditions with overlapping symptoms of depression, impulsivity, mood lability, anxiety, cognitive dysfunction, and psychosis.

  • Major Depressive Disorder (MDD): The most critical differential diagnosis. MDD lacks manic or hypomanic episodes. Careful history taking for past manic/hypomanic symptoms is crucial. Early onset, psychotic features, psychomotor retardation, atypical depression, and antidepressant-induced switching favor bipolar depression.

  • Schizophrenia and Schizoaffective Disorder: Psychotic symptoms are prominent in schizophrenia, but mood episodes are less central. Schizoaffective disorder involves both psychotic and prominent mood episodes, but the temporal relationship differs from BD. In schizoaffective disorder, psychotic symptoms persist even during periods of mood stability, unlike BD.

  • Anxiety Disorders (Generalized Anxiety Disorder, Panic Disorder, Social Anxiety Disorder): Anxiety is common in BD, but primary anxiety disorders lack the distinct mood episodes of mania/hypomania and depression. However, comorbid anxiety disorders are frequent in BD and need to be addressed separately.

  • Substance Use Disorders: Substance use can induce mood symptoms mimicking mania or depression. Substance-induced mood disorder should be considered if mood symptoms are directly linked to substance use. Comorbid substance use disorders are also common in BD and complicate diagnosis and treatment.

  • Borderline Personality Disorder (BPD): BPD shares mood lability, impulsivity, and suicidal behavior with BD. However, mood shifts in BPD are typically more rapid, reactive to interpersonal events, and lack the distinct episodic nature of bipolar mood episodes. Comorbidity of BPD and BD is also recognized.

  • Attention-Deficit/Hyperactivity Disorder (ADHD) and Oppositional Defiant Disorder (ODD) (in children/adolescents): ADHD can present with hyperactivity, impulsivity, and distractibility, resembling hypomania. ODD involves irritability and mood dysregulation. In children, differentiating early-onset bipolar disorder from ADHD and ODD is challenging. The episodic nature of mood changes and family history of BD are crucial differentiating factors.

Prognosis and Complications: Implications for Accurate Diagnosis

Bipolar disorder is a leading cause of disability and is associated with reduced life expectancy, approximately 13 years of potential life lost. Mortality rates are double that of the general population, with increased risks of both natural deaths (cardiovascular, respiratory illnesses) and unnatural deaths (suicide, accidents). Suicide risk in BD is significantly elevated, 20- to 30-fold higher than in the general population.

Complications of BD include increased risk of premature death, medical comorbidities (cardiovascular, metabolic syndrome, migraine), and psychiatric comorbidities (anxiety disorders, substance use disorders, personality disorders). Comorbidities worsen the course of BD, increase episode frequency, and reduce quality of life.

Accurate and timely differential diagnosis of bipolar disorder is critical for improving prognosis and reducing complications. Early and appropriate treatment, guided by accurate diagnosis, can significantly improve long-term outcomes, reduce episode frequency and severity, and improve quality of life and life expectancy for individuals with bipolar disorder. Misdiagnosis and delayed treatment can lead to poorer outcomes and increased risk of complications.

Deterrence, Patient Education, and Collaborative Care in Enhancing Diagnostic Accuracy

Psychoeducation for patients and families is essential, focusing on recognizing and managing prodromal symptoms of mania and depression, enhancing medication adherence, and promoting healthy lifestyle choices. Avoiding stimulants, minimizing alcohol, regular exercise, and good sleep hygiene are encouraged.

Building a strong therapeutic alliance, demonstrating empathy, involving patients in treatment decisions, and consistent symptom monitoring are crucial for improving outcomes and patient satisfaction. Collaborative care models, involving interprofessional teams including psychiatrists, primary care physicians, nurses, social workers, and pharmacists, are vital for comprehensive management of BD and comorbid conditions.

An interprofessional team approach enhances diagnostic accuracy by bringing diverse perspectives and expertise to patient evaluation. Collaborative care ensures holistic and integrated care, leading to better outcomes and fewer adverse events. Regular team meetings, shared decision-making, and clear communication among team members are key to optimizing patient care and refining diagnostic clarity over time.

Conclusion

Accurate differential diagnosis is paramount in the management of bipolar disorder. Distinguishing bipolar disorder from other psychiatric and medical conditions requires a thorough clinical evaluation, careful history taking, and consideration of various diagnostic criteria. Understanding the nuances of symptom overlap, particularly with major depressive disorder, schizophrenia spectrum disorders, anxiety disorders, personality disorders, and substance use disorders, is essential for clinicians. Early and accurate diagnosis, coupled with comprehensive and collaborative treatment approaches, is critical for improving the prognosis and long-term outcomes for individuals living with bipolar disorder.

References

  1. Chakrabarti S. Bipolar disorder in the International Classification of Diseases-Eleventh version: A review of the changes, their basis, and usefulness. World J Psychiatry. 2022 Dec 19;12(12):1335-1355.
  2. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, Viana MC, Andrade LH, Hu C, Karam EG, Ladea M, Medina-Mora ME, Ono Y, Posada-Villa J, Sagar R, Wells JE, Zarkov Z. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011 Mar;68(3):241-51.
  3. McGuffin P, Rijsdijk F, Andrew M, Sham P, Katz R, Cardno A. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry. 2003 May;60(5):497-502.
  4. Barnett JH, Smoller JW. The genetics of bipolar disorder. Neuroscience. 2009 Nov 24;164(1):331-43.
  5. Craddock N, Sklar P. Genetics of bipolar disorder. Lancet. 2013 May 11;381(9878):1654-62.
  6. Rybakowski J. Etiopathogenesis of bipolar affective disorder – the state of the art for 2021. Psychiatr Pol. 2021 Jun 30;55(3):481-496.
  7. Rowland TA, Marwaha S. Epidemiology and risk factors for bipolar disorder. Ther Adv Psychopharmacol. 2018 Sep;8(9):251-269.
  8. Miklowitz DJ, Johnson SL. The psychopathology and treatment of bipolar disorder. Annu Rev Clin Psychol. 2006;2:199-235.
  9. Ching CRK, Hibar DP, Gurholt TP, Nunes A, Thomopoulos SI, Abé C, Agartz I, Brouwer RM, Cannon DM, de Zwarte SMC, Eyler LT, Favre P, Hajek T, Haukvik UK, Houenou J, Landén M, Lett TA, McDonald C, Nabulsi L, Patel Y, Pauling ME, Paus T, Radua J, Soeiro-de-Souza MG, Tronchin G, van Haren NEM, Vieta E, Walter H, Zeng LL, Alda M, Almeida J, Alnaes D, Alonso-Lana S, Altimus C, Bauer M, Baune BT, Bearden CE, Bellani M, Benedetti F, Berk M, Bilderbeck AC, Blumberg HP, Bøen E, Bollettini I, Del Mar Bonnin C, Brambilla P, Canales-Rodríguez EJ, Caseras X, Dandash O, Dannlowski U, Delvecchio G, Díaz-Zuluaga AM, Dima D, Duchesnay É, Elvsåshagen T, Fears SC, Frangou S, Fullerton JM, Glahn DC, Goikolea JM, Green MJ, Grotegerd D, Gruber O, Haarman BCM, Henry C, Howells FM, Ives-Deliperi V, Jansen A, Kircher TTJ, Knöchel C, Kramer B, Lafer B, López-Jaramillo C, Machado-Vieira R, MacIntosh BJ, Melloni EMT, Mitchell PB, Nenadic I, Nery F, Nugent AC, Oertel V, Ophoff RA, Ota M, Overs BJ, Pham DL, Phillips ML, Pineda-Zapata JA, Poletti S, Polosan M, Pomarol-Clotet E, Pouchon A, Quidé Y, Rive MM, Roberts G, Ruhe HG, Salvador R, Sarró S, Satterthwaite TD, Schene AH, Sim K, Soares JC, Stäblein M, Stein DJ, Tamnes CK, Thomaidis GV, Upegui CV, Veltman DJ, Wessa M, Westlye LT, Whalley HC, Wolf DH, Wu MJ, Yatham LN, Zarate CA, Thompson PM, Andreassen OA., ENIGMA Bipolar Disorder Working Group. What we learn about bipolar disorder from large-scale neuroimaging: Findings and future directions from the ENIGMA Bipolar Disorder Working Group. Hum Brain Mapp. 2022 Jan;43(1):56-82.
  10. Scaini G, Valvassori SS, Diaz AP, Lima CN, Benevenuto D, Fries GR, Quevedo J. Neurobiology of bipolar disorders: a review of genetic components, signaling pathways, biochemical changes, and neuroimaging findings. Braz J Psychiatry. 2020 Sep-Oct;42(5):536-551.
  11. Kato T. Current understanding of bipolar disorder: Toward integration of biological basis and treatment strategies. Psychiatry Clin Neurosci. 2019 Sep;73(9):526-540.
  12. Nowrouzi B, McIntyre RS, MacQueen G, Kennedy SH, Kennedy JL, Ravindran A, Yatham L, De Luca V. Admixture analysis of age at onset in first episode bipolar disorder. J Affect Disord. 2016 Sep 01;201:88-94.
  13. Moreno C, Laje G, Blanco C, Jiang H, Schmidt AB, Olfson M. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatry. 2007 Sep;64(9):1032-9.
  14. Kroon JS, Wohlfarth TD, Dieleman J, Sutterland AL, Storosum JG, Denys D, de Haan L, Sturkenboom MC. Incidence rates and risk factors of bipolar disorder in the general population: a population-based cohort study. Bipolar Disord. 2013 May;15(3):306-13.
  15. Van Meter AR, Youngstrom EA, Findling RL. Cyclothymic disorder: a critical review. Clin Psychol Rev. 2012 Jun;32(4):229-43.
  16. Konopaske GT, Lange N, Coyle JT, Benes FM. Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder. JAMA Psychiatry. 2014 Dec 01;71(12):1323-31.
  17. Dagani J, Signorini G, Nielssen O, Bani M, Pastore A, Girolamo G, Large M. Meta-analysis of the Interval between the Onset and Management of Bipolar Disorder. Can J Psychiatry. 2017 Apr;62(4):247-258.
  18. McIntyre RS, Berk M, Brietzke E, Goldstein BI, López-Jaramillo C, Kessing LV, Malhi GS, Nierenberg AA, Rosenblat JD, Majeed A, Vieta E, Vinberg M, Young AH, Mansur RB. Bipolar disorders. Lancet. 2020 Dec 05;396(10265):1841-1856.
  19. Angst J, Cui L, Swendsen J, Rothen S, Cravchik A, Kessler RC, Merikangas KR. Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication. Am J Psychiatry. 2010 Oct;167(10):1194-201.
  20. Wang YY, Xu DD, Liu R, Yang Y, Grover S, Ungvari GS, Hall BJ, Wang G, Xiang YT. Comparison of the screening ability between the 32-item Hypomania Checklist (HCL-32) and the Mood Disorder Questionnaire (MDQ) for bipolar disorder: A meta-analysis and systematic review. Psychiatry Res. 2019 Mar;273:461-466.
  21. Mitchell PB, Goodwin GM, Johnson GF, Hirschfeld RM. Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disord. 2008 Feb;10(1 Pt 2):144-52.
  22. Bobo WV. The Diagnosis and Management of Bipolar I and II Disorders: Clinical Practice Update. Mayo Clin Proc. 2017 Oct;92(10):1532-1551.
  23. Parker GB, Graham RK, Tavella G. Is there consensus across international evidence-based guidelines for the management of bipolar disorder? Acta Psychiatr Scand. 2017 Jun;135(6):515-526.
  24. Gomes FA, Cerqueira RO, Lee Y, Mansur RB, Kapczinski F, McIntyre RS, Yatham LN, Berk M, Milev R, Brietzke E. What not to use in bipolar disorders: A systematic review of non-recommended treatments in clinical practice guidelines. J Affect Disord. 2022 Feb 01;298(Pt A):565-576.
  25. National Collaborating Centre for Mental Health (UK). Bipolar Disorder: The NICE Guideline on the Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care. The British Psychological Society and The Royal College of Psychiatrists; London: Sep, 2014.
  26. Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T, Cipriani A, Coghill DR, Fazel S, Geddes JR, Grunze H, Holmes EA, Howes O, Hudson S, Hunt N, Jones I, Macmillan IC, McAllister-Williams H, Miklowitz DR, Morriss R, Munafò M, Paton C, Saharkian BJ, Saunders K, Sinclair J, Taylor D, Vieta E, Young AH. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016 Jun;30(6):495-553.
  27. Fountoulakis KN, Grunze H, Vieta E, Young A, Yatham L, Blier P, Kasper S, Moeller HJ. The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines. Int J Neuropsychopharmacol. 2017 Feb 01;20(2):180-195.
  28. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, Sharma V, Goldstein BI, Rej S, Beaulieu S, Alda M, MacQueen G, Milev RV, Ravindran A, O’Donovan C, McIntosh D, Lam RW, Vazquez G, Kapczinski F, McIntyre RS, Kozicky J, Kanba S, Lafer B, Suppes T, Calabrese JR, Vieta E, Malhi G, Post RM, Berk M. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018 Mar;20(2):97-170.
  29. Shah N, Grover S, Rao GP. Clinical Practice Guidelines for Management of Bipolar Disorder. Indian J Psychiatry. 2017 Jan;59(Suppl 1):S51-S66.
  30. Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet. 2016 Apr 09;387(10027):1561-1572.
  31. Ferrari AJ, Stockings E, Khoo JP, Erskine HE, Degenhardt L, Vos T, Whiteford HA. The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013. Bipolar Disord. 2016 Aug;18(5):440-50.
  32. Chan JKN, Tong CHY, Wong CSM, Chen EYH, Chang WC. Life expectancy and years of potential life lost in bipolar disorder: systematic review and meta-analysis. Br J Psychiatry. 2022 Sep;221(3):567-576.
  33. Hayes JF, Miles J, Walters K, King M, Osborn DP. A systematic review and meta-analysis of premature mortality in bipolar affective disorder. Acta Psychiatr Scand. 2015 Jun;131(6):417-25.
  34. Plans L, Barrot C, Nieto E, Rios J, Schulze TG, Papiol S, Mitjans M, Vieta E, Benabarre A. Association between completed suicide and bipolar disorder: A systematic review of the literature. J Affect Disord. 2019 Jan 01;242:111-122.
  35. Roshanaei-Moghaddam B, Katon W. Premature mortality from general medical illnesses among persons with bipolar disorder: a review. Psychiatr Serv. 2009 Feb;60(2):147-56.
  36. Maina G, Salvi V, Vitalucci A, D’Ambrosio V, Bogetto F. Prevalence and correlates of overweight in drug-naïve patients with bipolar disorder. J Affect Disord. 2008 Sep;110(1-2):149-55.
  37. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. 2005 Oct;7(5):424-30.
  38. Fagiolini A, Kupfer DJ, Houck PR, Novick DM, Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry. 2003 Jan;160(1):112-7.
  39. Hossain S, Mainali P, Bhimanadham NN, Imran S, Ahmad N, Patel RS. Medical and Psychiatric Comorbidities in Bipolar Disorder: Insights from National Inpatient Population-based Study. Cureus. 2019 Sep 12;11(9):e5636.
  40. Yapici Eser H, Kacar AS, Kilciksiz CM, Yalçinay-Inan M, Ongur D. Prevalence and Associated Features of Anxiety Disorder Comorbidity in Bipolar Disorder: A Meta-Analysis and Meta-Regression Study. Front Psychiatry. 2018;9:229.
  41. Messer T, Lammers G, Müller-Siecheneder F, Schmidt RF, Latifi S. Substance abuse in patients with bipolar disorder: A systematic review and meta-analysis. Psychiatry Res. 2017 Jul;253:338-350.
  42. Onyeka IN, Collier Høegh M, Nåheim Eien EM, Nwaru BI, Melle I. Comorbidity of Physical Disorders Among Patients With Severe Mental Illness With and Without Substance Use Disorders: A Systematic Review and Meta-Analysis. J Dual Diagn. 2019 Jul-Sep;15(3):192-206.
  43. Latalova K, Prasko J, Kamaradova D, Sedlackova J, Ociskova M. Comorbidity bipolar disorder and personality disorders. Neuro Endocrinol Lett. 2013;34(1):1-8.
  44. McElroy SL, Winham SJ, Cuellar-Barboza AB, Colby CL, Ho AM, Sicotte H, Larrabee BR, Crow S, Frye MA, Biernacka JM. Bipolar disorder with binge eating behavior: a genome-wide association study implicates PRR5-ARHGAP8. Transl Psychiatry. 2018 Feb 02;8(1):40.
  45. Fisher A, Manicavasagar V, Kiln F, Juraskova I. Communication and decision-making in mental health: A systematic review focusing on Bipolar disorder. Patient Educ Couns. 2016 Jul;99(7):1106-1120.
  46. Susman JL. Improving outcomes in patients with bipolar disorder through establishing an effective treatment team. Prim Care Companion J Clin Psychiatry. 2010;12(Suppl 1):30-4.
  47. Salloum IM, Thase ME. Impact of substance abuse on the course and treatment of bipolar disorder. Bipolar Disord. 2000 Sep;2(3 Pt 2):269-80.
  48. van der Voort TY, van Meijel B, Goossens PJ, Hoogendoorn AW, Draisma S, Beekman A, Kupka RW. Collaborative care for patients with bipolar disorder: randomised controlled trial. Br J Psychiatry. 2015 May;206(5):393-400.
  49. Kern JS, Cerimele JM. Collaborative Care for Patients With a Bipolar Disorder: A Primary Care FQHC-CMHC Partnership. Psychiatr Serv. 2019 Apr 01;70(4):353.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *